Professor MD - Allarity Therapeutics CoFounder
| ALLR Stock | USD 1.26 0.07 5.88% |
Insider
Professor MD is CoFounder of Allarity Therapeutics
| Age | 67 |
| Address | 24 School Street, Boston, MA, United States, 02108 |
| Phone | 401 426 4664 |
| Web | https://www.allarity.com |
Allarity Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4772) % which means that it has lost $0.4772 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2182) %, meaning that it created substantial loss on money invested by shareholders. Allarity Therapeutics' management efficiency ratios could be used to measure how well Allarity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Allarity Therapeutics' Return On Capital Employed is relatively stable compared to the past year. As of 11/22/2024, Return On Equity is likely to grow to 4.54, while Return On Tangible Assets are likely to drop (6.28). At this time, Allarity Therapeutics' Total Assets are relatively stable compared to the past year. As of 11/22/2024, Non Current Assets Total is likely to grow to about 17.3 M, while Total Current Assets are likely to drop slightly above 1.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| DSc MSE | Immix Biopharma | 75 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| MBA MD | Immix Biopharma | 49 | |
| James Foster | Virax Biolabs Group | 39 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Nandan BS | Immix Biopharma | 62 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Donald Picker | Cns Pharmaceuticals | 78 | |
| CPA CTP | Cns Pharmaceuticals | 44 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Gabriel BA | Immix Biopharma | 37 | |
Management Performance
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.48 |
Allarity Therapeutics Leadership Team
Elected by the shareholders, the Allarity Therapeutics' board of directors comprises two types of representatives: Allarity Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allarity. The board's role is to monitor Allarity Therapeutics' management team and ensure that shareholders' interests are well served. Allarity Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allarity Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Professor MD, CoFounder | ||
| Joan Brown, Interim Reporting | ||
| Alexander Epshinsky, Chief Officer | ||
| James JD, Chief CEO | ||
| Jeremy Graff, President Officer | ||
| Steen Knudsen, Founder Officer | ||
| Annie Rasmussen, Chief Operations | ||
| Claus Pedersen, Chief Officer | ||
| Jose MD, Consultant Officer | ||
| MD DrSc, Chief Officer | ||
| Thomas Jensen, CEO, Founder |
Allarity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allarity Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.48 | ||||
| Current Valuation | (11.85 M) | ||||
| Shares Outstanding | 1.41 M | ||||
| Shares Owned By Insiders | 12.30 % | ||||
| Shares Owned By Institutions | 1.20 % | ||||
| Number Of Shares Shorted | 179.44 K | ||||
| Price To Book | 0.41 X | ||||
| Gross Profit | (36.35 M) | ||||
| EBITDA | (12.08 M) |
Pair Trading with Allarity Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allarity Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allarity Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allarity Stock
| 0.91 | VRAX | Virax Biolabs Group | PairCorr |
| 0.7 | VRPX | Virpax Pharmaceuticals | PairCorr |
| 0.76 | DYN | Dyne Therapeutics | PairCorr |
Moving against Allarity Stock
| 0.91 | VRDN | Viridian Therapeutics | PairCorr |
| 0.86 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.79 | PRAX | Praxis Precision Med | PairCorr |
| 0.75 | AMLX | Amylyx Pharmaceuticals | PairCorr |
| 0.7 | AKRO | Akero Therapeutics | PairCorr |
The ability to find closely correlated positions to Allarity Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allarity Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allarity Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allarity Therapeutics to buy it.
The correlation of Allarity Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allarity Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allarity Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allarity Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Allarity Stock Analysis
When running Allarity Therapeutics' price analysis, check to measure Allarity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allarity Therapeutics is operating at the current time. Most of Allarity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allarity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allarity Therapeutics' price. Additionally, you may evaluate how the addition of Allarity Therapeutics to your portfolios can decrease your overall portfolio volatility.